Adjustment of open-loop settings to improve closed-loop results in type 1 diabetes: A multicenter randomized trial

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages 3878-3886

  Dassau, Eyal ^a,b   Brown, Sue A ^c   Basu, Ananda ^d   Pinsker, Jordan E ^a,b   Kudva, Yogish C ^d   Gondhalekar, Ravi ^a,b   Patek, Steve ^c   Lv, Dayu ^c   Schiavon, Michele ^e   Lee, Joon Bok ^a,b   Dalla Man, Chiara ^e   Hinshaw, Ling ^d   Castorino, Kristin ^a   Mallad, Ashwini ^d   Dadlani, Vikash ^d   McCrady Spitzer, Shelly K ^d   McElwee Malloy, Molly ^c   Wakeman, Christian A ^c   Bevier, Wendy C ^a   Bradley, Paige K ^b   Kovatchev, Boris ^c   Cobelli, Claudio ^e   Zisser, Howard C ^a,b   Doyle, Francis J ^a,b   more..

^a University of California   (United States)

^b William Sansum Diabetes Center   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLOSED LOOP CONTROL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAFETY; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943792254     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2081     Document Type: Article

References (27)

1. Pickup JC, Keen H, Parsons JA, Alberti KG. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J. 1978;1:204-207.
2. Tamborlane WV, Sherwin RS, Genel M, Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N Engl J Med. 1979;300:573-578.
3. Turksoy K, Quinn L, Littlejohn E, Cinar A. Multivariable adaptive identification and control for artificial pancreas systems. IEEE Trans Biomed Eng. 2014;61:883-891.
4. Russell SJ, El-Khatib FH, SinhaM,Magyar KL,McKeonK, Goergen LG, Balliro C, Hillard MA, Nathan DM, Damiano ER. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313-325.
5. Nimri R, Phillip M. Artificial pancreas: fuzzy logic and control of glycemia. Curr Opin Endocrinol Diabetes Obes. 2014;21:251-256.
6. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closedloop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care. 2014;37:1789-1796.
7. Harvey RA, Dassau E, Bevier WC, et al. Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system. Diabetes Technol Ther. 2014;16: 348-357.
8. El-Khatib FH, Russell SJ, Magyar KL, et al. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab. 2014; 99:1701-1711.
9. Steil GM. Algorithms for a closed-loop artificial pancreas: The case for proportional-integral-derivative control. J Diabetes Sci Technol. 2013;7:1621-1631.
10. Mauseth R, Hirsch IB, Bollyky J, et al. Use of a "fuzzy logic" controller in a closed-loop artificial pancreas. Diabetes Technol Ther. 2013;15:628-633.
11. Dassau E, Zisser H, Harvey RA, et al. Clinical evaluation of a personalized artificial pancreas. Diabetes Care. 2013;36:801-809.
12. Nimri R, Muller I, Atlas E, Miller S, et al. Night glucose control with MD-Logic artificial pancreas in home setting: A single blind, randomized crossover trial-interim analysis. Pediatr Diabetes. 2014; 15:91-99.
13. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, singlehormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 2015;3:17-26.
14. Cameron F, Niemeyer G, Wilson DM, et al. Inpatient trial of an artificial pancreas based on multiple model probabilistic predictive control with repeated large unannounced meals. Diabetes Technol Ther. 2014;16:728-734.
15. Thabit H, Lubina-Solomon A, Stadler M, et al. Home use of closedloop insulin delivery for overnight glucose control in adults with type 1 diabetes: A 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2014;2:701-709.
16. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: threecenter randomized crossover study. Diabetes Care. 2014;37:1931-1937.
17. Hovorka R, Elleri D, Thabit H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: A free-living, randomized clinical trial. Diabetes Care. 2014;37:1204-1211.
18. Zisser H, Renard E, Kovatchev B, et al, Control to Range Study Group. Multicenter closed-loop insulin delivery study points to challenges for keeping blood glucose in a safe range by a control algorithm in adults and adolescents with type 1 diabetes from various sites. Diabetes Technol Ther. 2014;16:613-622.
19. Kovatchev BP, Mendosa P, Anderson S, Hawley JS, Ritterband LM, Gonder-Frederick L. Effect of automated bio-behavioral feedback on the control of type 1 diabetes. Diabetes Care. 2011;34:302-307.
20. Grosman B, Dassau E, Zisser HC, Jovanovič L, Doyle III FJ. Zone model predictive control: A strategy to minimize hyper-and hypoglycemic events. J Diabetes Sci Technol. 2010;4:961-975.
21. Harvey RA, Dassau E, Zisser H, Seborg DE, Jovanovič L, Doyle III FJ. Design of the health monitoring system for the artificial pancreas: low glucose prediction module. J Diabetes Sci Technol. 2012;6: 1345-1354.
22. Gondhalekar R, Dassau E, Zisser HC, Doyle III FJ. Periodic-zone model predictive control for diurnal closed-loop operation of an artificial pancreas. J Diabetes Sci Technol. 2013;7:1446-1460.
23. Gondhalekar R, Dassau E, Doyle III FJ.MPCdesign for rapid pumpattenuation and expedited hyperglycemia response to treat T1DM with an artificial pancreas. Paper presented at: American Control Conference 2014; Portland, OR
24. Dassau E, Zisser H, Palerm CC, Buckingham BA, Jovanovič L, Doyle III FJ. Modular artificial-cell system: A prototype for clinical research. J Diabetes Sci Technol. 2008;2:863-872.
25. Kovatchev BP, StraumeM,Cox DJ, Farhy LS. Risk analysis of blood glucose data: A quantitative approach to optimizing the control of insulin dependent diabetes. Comput Math Methods Med. 2000;3: 1-10.
26. SnedecorGW,CochranWG.Statistical Methods. 8th ed. Iowa State University Press; Ames, IA.
27. Hinshaw L, Dalla Man C, Nandy DK, et al. Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system. Diabetes. 2013;62:2223-2229.